International Cancer Conference Journal最新文献

{"title":"Penile mucoepidermoid carcinoma lacking <i>CRTC1/CRTC3-MAML2</i> fusion: a case report and review of the literature.","authors":"Satoshi Ohno, Shinro Hata, Kazuhiro Kawamura, Yuzo Oyama, Masahiro Todaka, Satoki Abe, Shuntaro Suzuki, Hiroyuki Fujinami, Tsutomu Daa, Toshitaka Shin","doi":"10.1007/s13691-025-00828-0","DOIUrl":"https://doi.org/10.1007/s13691-025-00828-0","url":null,"abstract":"<p><p>Penile cancer is a rare malignancy, with squamous cell carcinoma (SCC) being the predominant histological type. Mucoepidermoid carcinoma (MEC) of the penis is an extremely rare variant, making its clinicopathological features and prognosis poorly understood. We report the case of an 87-year-old man who presented with penile swelling and an ulcerative lesion. An initial biopsy initially suggested SCC. However, histopathological analysis of the total penectomy specimen revealed features consistent with MEC, characterized by a mixture of mucin-producing squamoid and intermediate cells. The tumor appeared to originate from the transitional zone between the prepuce and glans. Importantly, molecular analysis did not detect the <i>CRTC1/CRTC3</i>-<i>MAML2</i> fusion gene, a finding potentially associated with a poorer prognosis. This case highlights a rare and challenging diagnosis of penile cancer. The absence of the common MEC-associated fusion gene may indicate a more aggressive clinical course. Further accumulation of cases with detailed molecular characterization is crucial to clarify the pathogenesis, behavior, and optimal management strategies for this rare entity.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"15 1","pages":"121-125"},"PeriodicalIF":0.5,"publicationDate":"2025-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12831712/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146051937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of endometrioid carcinoma of the endometrium that progressed to lethal neuroendocrine carcinoma as a result of <i>TMEM178B-BRAF</i> fusion.","authors":"Yoko Kashima, Hisamitu Takaya, Chiho Miyagawa, Tomoyuki Otani, Kazuko Sakai, Kazuto Nishio, Noriomi Matsumura","doi":"10.1007/s13691-025-00823-5","DOIUrl":"https://doi.org/10.1007/s13691-025-00823-5","url":null,"abstract":"<p><p>Endometrial cancer is generally associated with a favorable prognosis when detected at an early stage and treated appropriately, especially in young women receiving fertility-sparing therapy. However, rare cases may exhibit unexpected aggressive progression driven by novel genetic alterations.A 38-year-old woman was diagnosed with stage IA endometrial endometrioid carcinoma grade 1, based on pathologic examination by endometrial curettage, magnetic resonance imaging, and computed tomography scans. The tumour progressed systemically during fertility-sparing treatment and she died on day 112. Pathologic examination of the liver metastasis revealed that the tumour was morphologically different from the endometrial tumour and was oestrogen receptor-negative, chromogranin A-positive, and synaptophysin-positive on immunohistochemistry, leading to the diagnosis of neuroendocrine carcinoma. Gene panel testing identified <i>TMEM178B-BRAF</i> fusion and subclonal <i>PIK3CA</i> mutations in the liver metastasis, in addition to <i>ARID1A</i> and <i>CTNNB1</i> mutations that were shared with the endometrial tumour. This is the first report of an endometrioid carcinoma transforming into a high-grade neuroendocrine tumour associated with <i>TMEM178B-BRAF</i> fusion.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"15 1","pages":"99-102"},"PeriodicalIF":0.5,"publicationDate":"2025-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12831697/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146051955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of leiomyosarcoma during long-term levonorgestrel intrauterine system (LNG-IUS) insertion.","authors":"Yoko Suzuki, Kenji Kuroda, Hiroko Nakagami, Ken Kuriki, Hiromitsu Shinohara, Kazutoshi Naritaka","doi":"10.1007/s13691-025-00817-3","DOIUrl":"https://doi.org/10.1007/s13691-025-00817-3","url":null,"abstract":"<p><p>We present a case highlighting the importance of monitoring patients with leiomyoma degeneration undergoing long-term local hormonal therapy using a levonorgestrel-releasing intrauterine system (LNG-IUS). Retrospective ultrasonographic observations over 7 years revealed sequential changes in a mass at the exact location, allowing early detection of malignancy. Histological examination confirmed that malignant leiomyosarcoma cells have replaced benign smooth muscle cells. This finding underscores the need for advised monitoring of LNG-IUS users, particularly in patients with leiomyoma degeneration changes. Further research is warranted to investigate the potential association between prolonged use of LNG-IUS and the development of leiomyosarcoma. To our knowledge, this is the first reported case of leiomyosarcoma arising during the insertion of an LNG-IUS.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"15 1","pages":"92-98"},"PeriodicalIF":0.5,"publicationDate":"2025-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12831765/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146051957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute esophageal mucosal injury during pembrolizumab treatment after a hypopharyngeal cancer patient's free jejunal autograft reconstruction, as an immune-related adverse event.","authors":"Yuten Shuri, Kenji Nakano, Koichi Takeda, Toru Sasaki, Tetsuya Urasaki, Makiko Ono, Toshiaki Mochizuki, Takahiro Kogawa, Taro Shiga, Shigehisa Kitano, Xiaofei Wang, Hirotaka Suto, Ryosuke Oki, Naoki Fukuda, Junichi Tomomatsu, Hiroki Mitani, Shunji Takahashi, Yuji Miura","doi":"10.1007/s13691-025-00822-6","DOIUrl":"https://doi.org/10.1007/s13691-025-00822-6","url":null,"abstract":"<p><p>The upper gastrointestinal tract is a relatively rare site for immune-related adverse events (AEs) associated with immune checkpoint inhibitor treatment. A 79-year-old Japanese male with relapsed hypopharyngeal carcinoma after curative surgery with free-jejunum reconstruction and postoperative irradiation developed multiple lung metastases invading the mediastinum. Four months after the anti-PD-1 inhibitor pembrolizumab was initiated, repeated bleeding episodes occurred in the tracheostoma and mouth. Tumor progression, collapse, and bleeding were not observed on CT. Esophagogastroduodenoscopy identified erosion of the reconstructed free jejunum and esophageal mucosal injury (diagnosed as an immune-related AE) as the bleeding source. A corticosteroid (methylprednisolone) was introduced, resulting in a rapid response. Considering the risk of esophageal perforation/bleeding and the patient's age, best supportive care and the termination of systemic chemotherapy were recommended. Acute esophagitis as irAE can be fatal, necessitating its early differentiation and corticosteroid treatment. Further clarification of the predilection and time course of this AE is warranted.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"15 1","pages":"86-91"},"PeriodicalIF":0.5,"publicationDate":"2025-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12831696/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146051408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lanreotide acetate subcutaneous injection-induced granulomatous inflammation after surgery for neuroendocrine tumor of unknown primary origin.","authors":"Susumu Saigusa, Hiroyuki Sakurai, Hiroyuki Fujikawa, Shuyo Watanabe, Kosuke Fukumochi, Yo Uchiyama, Tomomi Mohri, Yoshifumi Hirokawa, Koji Tanaka","doi":"10.1007/s13691-025-00813-7","DOIUrl":"https://doi.org/10.1007/s13691-025-00813-7","url":null,"abstract":"<p><p>Lanreotide is a synthetic polypeptide analog of somatostatin that is used to treat gastroenteropancreatic neuroendocrine tumors (NETs). Although granulomatous inflammation is caused by a variety of conditions, lanreotide acetate subcutaneous injection-induced granulomatous inflammation has not been reported. A 53-year-old woman was underwent extirpation for NET on the anterior surface of pancreatic head. The pathological findings revealed that the resected specimen mainly consisted of lymph-node metastasis and diagnosed NET of unknown primary origin. Because there was a possibility of remnant of the primary tumor and a high risk of recurrence, she began monthly lanreotide acetate subcutaneous injections 1 month after NET surgery. Diffusion-weighted whole-body imaging with background signal suppression revealed a subcutaneous nodule with a high signal in the left buttock 2 months after surgery, which was suggestive of NET subcutaneous metastasis. A computed tomography scan 5 months after surgery revealed multiple subcutaneous nodules on the buttocks bilaterally. Because the number of subcutaneous nodules on the buttocks increased over time, an excisional biopsy of the nodule was obtained. The subcutaneous nodule was diagnosed as granulomatous inflammation based on the histopathologic evaluation. Clinicians should be aware that subcutaneous injection of lanreotide acetate may cause granulomatous inflammation, resulting in subcutaneous nodules that may be misdiagnosed as subcutaneous metastases.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"15 1","pages":"80-85"},"PeriodicalIF":0.5,"publicationDate":"2025-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12831745/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146051939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ruptured mature cystic teratoma with granulomatous inflammation masquerading as pseudomyxoma peritonei.","authors":"Fenja Steinert, Jens Hölzen, Mazen Juratli, Jennifer Merten, Ralf Witteler, Eva Wardelmann, Andreas Pascher, Ann-Kathrin Eichelmann","doi":"10.1007/s13691-025-00818-2","DOIUrl":"https://doi.org/10.1007/s13691-025-00818-2","url":null,"abstract":"<p><p>Mature cystic teratomas are common benign ovarian neoplasms, but rupture is a rare complication, occurring in less than 5% of cases. Peritonitis with granulomatous lesions following rupture, mimicking peritoneal carcinomatosis, is extremely rare and is not typically reported as a complication. We report the case of a 48-year-old Caucasian female with lower abdominal pain and suspected four-quadrant peritonitis. A 7.9 cm teratoma was identified on CT scan. Exploratory laparoscopy revealed numerous adhesions and fibrinous exudate. Initially, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy were recommended due to a highly suspected malignancy, initially thought to be pseudomyxoma peritonei. However, laparotomy revealed over 50 encapsulated mucoid micronodular lesions and pronounced adhesions throughout the entire abdominal cavity. Despite the macroscopic appearance, no evidence of malignancy was found in any of the numerous frozen sections sent for analysis. Histopathology confirmed a mature cystic teratoma with multifocal foreign body granulomas. No malignancy was detected. It is likely that multiple (silent) ruptures of the mature cystic teratoma were responsible for this unusually pronounced inflammatory response in the whole abdomen. This case report presents a rare and unusual complication of a mature cystic teratoma, where it mimics peritoneal carcinomatosis, leading to an initial misdiagnosis. While ruptured mature cystic teratomas are known, the granulomatous inflammation and peritonitis that mimicked pseudomyxoma peritonei have not been reported in the literature. This novel presentation could significantly affect diagnostic protocols in similar cases, as it provides insight into how granulomatous reactions can present similarly to malignancy, potentially leading to unnecessary aggressive treatments such as cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"15 1","pages":"74-79"},"PeriodicalIF":0.5,"publicationDate":"2025-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12831728/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146051877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A rare case of mastitis involving granulomatosis with polyangiitis after immune checkpoint inhibitor therapy.","authors":"Chieko Mishima, Akane Watanabe, Yuichi Motoyama, Takahiro Kodama, Ryu Tokui, Yasufumi Sato, Nanae Masunaga, Masami Tsukabe, Yoshiaki Sota, Tetsuhiro Yoshinami, Tomonori Tanei, Kenzo Shimazu","doi":"10.1007/s13691-025-00816-4","DOIUrl":"10.1007/s13691-025-00816-4","url":null,"abstract":"<p><p>Immune-related adverse events (irAE) are a concern during immune checkpoint inhibitor therapy (ICI), and vasculitis is a rheumatic irAE. Granulomatosis with polyangiitis (GPA) is an anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis characterized by necrotizing granulomatosis. GPA in the mammary glands is rare and causes granulomatous mastitis. We describe an older woman with metastatic hepatocellular carcinoma who was receiving ICI therapy. She developed a rapidly growing painful mass in her right breast. Biopsy of the breast revealed necrotizing granulomatous mastitis, which implied an association with autoimmune disease. We detected c-ANCA (proteinase 3)-positivity and a nodule forming a cavity in her right lung; lung biopsy revealed granulomatosis. We diagnosed GPA, possibly arising as an irAE. Prompt initiation of prednisolone therapy led to complete resolution of clinical symptoms within 2 weeks. This case represents the first known report of rare autoimmune mastitis with GPA flared after ICI therapy.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"15 1","pages":"66-73"},"PeriodicalIF":0.4,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12831740/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146051969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lumbar intramedullary spinal cord metastasis from esophageal cancer treated with palliative radiotherapy: a case report.","authors":"Nobuko Utsumi, Hidemasa Kawamura, Takafumi Yamano, Toyokazu Hayakawa, Norifumi Mizuno, Shuichi Ueno, Mio Saito, Fumiharu Machida, Yusuke Matsumoto, Mariko Umeda, Yuito Kato, Youichi Kumagai, Takeo Takahashi","doi":"10.1007/s13691-025-00819-1","DOIUrl":"https://doi.org/10.1007/s13691-025-00819-1","url":null,"abstract":"<p><p>Intramedullary spinal cord metastasis (ISCM) is a rare condition. ISCM from esophageal cancer is extremely uncommon. We report a rare case of lumbar ISCM from esophageal cancer in a woman in her 70 s, initially diagnosed with clinical stage IVA (cT4bN1M0) esophageal cancer. She underwent definitive radiotherapy (60 Gy in 30 fractions) with concurrent chemotherapy of 5-fluorouracil and cisplatin (FP), followed by two additional cycles of FP chemotherapy. A complete response was maintained for 1 year and 7 months post-radiotherapy by endoscopy. However, the patient began to experience mild bladder and rectal dysfunction and back pain. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) revealed high FDG uptake in the spinal cord cavity at the L1 level and contrast-enhanced spinal magnetic resonance imaging (MRI) showed an intramedullary tumor corresponding to the areas of FDG accumulation. Based on the appearance of new lesions and elevated tumor markers, the lesion was diagnosed as ISCM from esophageal cancer rather than a primary spinal cord tumor, and palliative radiotherapy (20 Gy in 5 fractions) was promptly administered. Two months after radiotherapy, the patient's neurologic symptoms improved, and she continued treatment with immune chemotherapy. To our knowledge, this is the first reported case of immune checkpoint inhibitors after the diagnosis of ISCM from esophageal cancer. Although rare, ISCM should be considered in cancer patients presenting with new neurological symptoms, and timely multidisciplinary intervention is essential for optimal management.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"15 1","pages":"55-59"},"PeriodicalIF":0.5,"publicationDate":"2025-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12831768/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146051965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mitomycin, 5-fluorouracil, and radiotherapy for anal canal cancer in a patient undergoing hemodialysis: a case report.","authors":"Yuki Ozawa, Junichi Kusano, Ryusei Yamamoto, Mutsuhito Matsuda","doi":"10.1007/s13691-025-00821-7","DOIUrl":"10.1007/s13691-025-00821-7","url":null,"abstract":"<p><p>Anal cancer is a rare malignancy that accounts for only 0.3% of all cancer cases. Clinical data on treatment strategies for patients with special conditions, such as impaired renal function or those undergoing dialysis, are limited. Herein, we report a case highlighting the efficacy and safety of a combination regimen of mitomycin C (MMC), 5-fluorouracil (5-FU), and radiotherapy (RT) in a patient undergoing dialysis. A 65 year-old woman undergoing hemodialysis three times per week for chronic kidney disease associated with polycystic kidney disease presented with hematochezia. Biopsy confirmed human papillomavirus (HPV)-related anal squamous cell carcinoma, clinical stage cT1N0M0 (Stage I). The patient underwent two cycles of MMC and 5-FU combined with RT. The adverse events included grade 3 neutropenia, grade 3 thrombocytopenia, grade 2 nausea, grade 1 vomiting, and grade 3 diarrhea. Post-treatment endoscopic and histological evaluations confirmed a complete response. This case suggests that MMC + 5-FU + RT may be a viable treatment option with manageable toxicity, even in patients with anal canal cancer undergoing dialysis.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"15 1","pages":"60-64"},"PeriodicalIF":0.4,"publicationDate":"2025-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12831791/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146051915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathological features of PDGFRA D842Y-mutant gastrointestinal stromal tumors: insights from four cases.","authors":"Tatsuo Kanda, Hiroshi Ichikawa, Seiichi Hirota, Yusuke Tani, Takahiro Watanabe, Yamato Miwa, Yuta Ushida, Noriyuki Uesugi, Toshifumi Wakai","doi":"10.1007/s13691-025-00820-8","DOIUrl":"10.1007/s13691-025-00820-8","url":null,"abstract":"<p><p>Gastrointestinal stromal tumors (GISTs) harboring the <i>PDGFRA</i> D842Y mutation are extremely rare, and their clinicopathological features have not been characterized to date. Hyogo Medical University has maintained a genetic database of GISTs, including resection cases from Niigata University, since 2003. This database contains information on patient demographics, tumor genotypes (<i>KIT</i> and <i>PDGFRA</i>), tumor size, histological features, and immunohistochemical findings. As of December 2024, 1,024 primary GIST cases had been analyzed, and four cases harboring the <i>PDGFRA</i> D842Y mutation were identified and included in this study. All four patients (three men, aged 57-82 years) had large gastric tumors, measuring 9.8-18.7 cm in diameter. All tumors harbored a c.2527G > T substitution in exon 18 of <i>PDGFRA</i>, resulting in a D842Y mutation. Histologically, all tumors exhibited epithelioid morphology. KIT expression was absent or markedly reduced, whereas DOG1 was consistently strongly expressed. Three patients presented with an acute abdomen and subsequently underwent surgery. The remaining patient had an unresectable tumor and received tyrosine kinase inhibitor therapy; however, sequential treatment with imatinib and sunitinib was clinically ineffective. <i>PDGFRA</i> D842Y-mutant GISTs share histopathological features with D842V-mutant tumors, including gastric origin, epithelioid morphology, and low KIT expression. However, their clinical behavior differs: D842Y-mutant GISTs consistently present as large, hypervascular tumors associated with acute complications. The therapeutic efficacy of tyrosine kinase inhibitors remains unclear, underscoring the need for further case accumulation to better define the clinical course and determine optimal treatment strategies for this rare subtype.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"15 1","pages":"48-54"},"PeriodicalIF":0.4,"publicationDate":"2025-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12831784/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146051836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}